Clinical trials
Completed Attention Deficit Disorder with Hyperactivity trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shire | 7 |
| Eli Lilly and Company | 4 |
| Hospital Universitari Vall d'Hebron Research Institute | 2 |
| Janssen-Cilag International NV | 2 |
| Universitat de Girona | 2 |
| Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina | 1 |
| Fundació Sant Joan de Déu | 1 |
| Goethe University | 1 |
| Hospital Vall d'Hebron | 1 |
| Laboratorios Ordesa | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Attention Deficit Disorder with Hyperactivity | 29 |
| Autism Spectrum Disorder | 2 |
| Autistic Disorder | 2 |
| Bipolar Disorder | 1 |
| Borderline Personality Disorder | 1 |
| Compulsive Personality Disorder | 1 |
| Mental Disorders | 1 |
| Obesity | 1 |
| Oppositional Defiant Disorder | 1 |
| Personality Disorders | 1 |
Trials
Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.